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Background: In preclinical gastric cancer (GC) models, FGFR2 amplification was associated with increased tumour cell
proliferation and survival, and drugs targeting this pathway are now in clinical trials.
Methods: FGFR2 FISH was performed on 961 GCs from the United Kingdom, China and Korea, and the relationship with
clinicopathological data and overlap with HER2 amplification were analysed.
Results: The prevalence of FGFR2 amplification was similar between the three cohorts (UK 7.4%, China 4.6% and Korea 4.2%), and
intratumoral heterogeneity was observed in 24% of FGFR2 amplified cases. FGFR2 amplification was associated with lymph node
metastases (Po0.0001). FGFR2 amplification and polysomy were associated with poor overall survival (OS) in the Korean (OS: 1.83
vs 6.17 years, P¼ 0.0073) and UK (OS: 0.45 vs 1.9 years, Po0.0001) cohorts, and FGFR2 amplification was an independent marker of
poor survival in the UK cohort (P¼ 0.0002). Co-amplification of FGFR2 and HER2 was rare, and when high-level amplifications did
co-occur these were detected in distinct areas of the tumour.
Conclusion: A similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic
invasion and poor prognosis. This study also shows that HER2 and FGFR2 amplifications are mostly exclusive.
Despite a steady decline in incidence, gastric cancer (GC) is the
second most common cause of cancer-related deaths worldwide
(Jemal et al, 2011; GLOBOCAN statistics 2009). Most GC patients
in the East are diagnosed with early-stage disease (Naylor et al,
2006; Jemal et al, 2011; 2008), whereas GC patients in the West
present with locally advanced (inoperable), metastatic or recurrent
disease and are treated by cytotoxic combination chemotherapy
(Cunningham and Oliveira, 2008; Kang and Kauh, 2011; Bang,
2012). Median overall survival (OS) of patients treated with
palliative chemotherapy is 10–12 months (Cunningham and
Oliveira, 2008). Targeted therapy has been investigated in this
patient group, and the combination of trastuzumab with
chemotherapy demonstrated a modest OS benefit in patients with
HER2-positive advanced GC (Bang et al, 2010). However, no
survival benefit was seen when bevacizumab, an antibody against
VEGF (Van Cutsem et al, 2012a), everolimus, a drug targeting
mTOR (Van Cutsem et al, 2012b), or the EGFR antibodies
panitumumab or cetuximab (Lordick et al, 2013; Waddell et al,
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2012) were trialed in non-selected GC patients. Because of the poor
prognosis of GC patients, there is a need to identify new potential
targets and develop diagnostic tests to identify patients most likely
to benefit from targeted therapies.
Fibroblast growth factor receptors (FGFR1–4) are transmem-
brane tyrosine kinase receptors (Eswarakumar et al, 2005; Turner
and Grose, 2010; Brooks et al, 2012; Waddell et al, 2012). FGF
binding to the monomeric receptor triggers dimerisation and
transphosphorylation of tyrosine residues in the kinase domain
(Eswarakumar et al, 2005; Katoh and Katoh, 2006; Turner and
Grose, 2010; Brooks et al, 2012). This pathway regulates a variety
of cellular functions including cell proliferation, migration and
differentiation, which are fundamental to embryonic development,
angiogenesis and wound healing (Eswarakumar et al, 2005;
Fukumoto, 2008; Turner and Grose, 2010; Brooks et al, 2012).
Dysregulation of the FGFR signalling pathway due to receptor
overexpression, gene amplification, mutation or aberrant tran-
scriptional regulation is associated with cancer development and
progression in multiple myeloma and cancers of the breast,
bladder, lung, endometrium and prostate (Jang et al, 2001; Davies
et al, 2005; Grose and Dickson, 2005; Stephens et al, 2005; Katoh,
2010; Turner and Grose, 2010; Brooks et al, 2012).
In preclinical models of GC, FGFR2 amplification was
associated with increased tumour cell proliferation and survival,
and conferred sensitivity to drugs targeting this pathway, such as
the FGFR selective small molecule inhibitors AZD4547 and
BGJ398, and anti-FGFR2 antibodies (Bai et al, 2010; Zhao et al,
2010; Gavine et al, 2012; Guagnano et al, 2012; Zhang et al, 2012;
Xie et al, 2013). Studies have reported FGFR2 amplification in up
to 10% of Asian GC patients (Deng et al, 2012; Jung et al, 2012;
Matsumoto et al, 2012), and FGFR2 amplification was recently
described in Western GC cohorts (Deng et al, 2012; Dulak et al,
2012; Nadauld et al, 2012). Each of these studies employed a
different platform to assess gene amplification, including RT-PCR,
fluorescence in situ hybridisation (FISH) and SNP arrays.
This study used FISH to compare the frequency of FGFR2
amplification in large series of GCs from UK, Chinese and Korean
patients, the overlap of FGFR2 and HER2 amplification, and the
association of FGFR2 amplification with clinicopathological
variables and OS.
MATERIAL AND METHODS
Patient cohorts. The UK, Chinese and Korean GC cohorts
consisted of 408, 197 and 356 patients, respectively, with sporadic
gastric adenocarcinoma who underwent surgical resection at Leeds
General Infirmary, the United Kingdom (1970––2004), Shanghai
Renji Hospital, China (2007–2010) and Seoul National University
Hospital, South Korea (1996), respectively (Table 1). Clinical
outcome was determined from date of surgery until last seen or
mortality status obtained in 2009, 2011 and 2003, for the UK,
Chinese and Korean cohorts, respectively. At the end of the study
period, 73% and 33% of UK and Chinese patients had died.
Median (range) follow-up time was 1.7 years (0–20.5 years), 2.4
years (1 month–4.6 years) and 5.5 years (2 months–8 years) for
UK, Chinese and Korean cohorts, respectively.
Tissue microarray construction. Haematoxylin/eosin-stained
sections of resected specimens were reviewed, and blocks with
the highest tumour cell density selected for tissue microarray
(TMA) construction. TMAs were constructed by random sampling
of 3–6, 0.6mm cores from each tumour and three cores from
matched normal mucosa (UK cohort), one 1-mm core from each
tumour (Korean cohort), two to four 0.6-mm cores from each
tumour and two from matched normal mucosa (Chinese cohort).
Four (Korean/Chinese) or 5 mm (UK) sections were cut from each
TMA for gene copy-number analysis. Full sections were cut from
26 UK FGFR2-amplified GC specimens to assess amplification
heterogeneity within individual tumours. TMA and full sections
were quality controlled by an experienced histopathologist.
FGFR2 FISH. The FGFR2 FISH probe was generated in house by
AstraZeneca by directly labelling BAC RP11-62L18 (Invitrogen,
Grand Island, New York, USA) DNA with Spectrum Red (ENZO,
Exeter, UK, 02N34-050) using a nick translation-based method
(Abbott Park, IL, USA, 07J00-001) according to the manufacturer’s
instructions. Pericentromeric Spectrum Green labelled chromo-
some 10 probe (CEP10, Vysis, 32-132010) was used as an internal
control. FISH was performed as described previously (Xie et al,
2013). Sections were deparaffinized and pretreated using the
SpotLight Tissue Kit (Invitrogen, 00–8401) according to the
manufacturer’s instructions. Sections and FGFR2/CEP10 probes
were co-denaturated at 80 1C for 5min and hybridised at 37 1C for
48 h. Excess probe was removed with post-hybridisation wash
buffer (0.3% NP40/1 SSC) at 75.5 1C for 5min, then 2 SSC at
room temperature for 2min. Sections were counterstained with
0.3 mgml 1 DAPI (Vector, H-1200) and coverslipped. FGFR2 and
CEP10 signals were scored under a fluorescence microscope
(Olympus, Center Valley, PA, USA, BX61). Scoring was adopted
from (Varella-Garcia, 2006). Fifty nuclei were evaluated/case.
FGFR2 gene copy-number and FGFR2/CEP10 ratio was classified
as follows: FGFR2 amplification (score 6): FGFR2/CEP10 ratioX2
or FGFR2 gene clusters in X10% tumour cells; high polysomy
(score 5): FGFR2/CEP10 ratio o2 and X4 copies of FGFR2 in
X40% tumour cells; low polysomy (score 4): FGFR2/CEP10 ratio
o2 and X4 copies of FGFR2 in 10–39% tumour cells; high
trisomy (score 3): FGFR2/CEP10 ratio o2 and 3 copies of FGFR2
in Z40% tumour cells and o10% tumour cells having X4 copies
of FGFR2; low trisomy (score 2): FGFR2/CEP10 ratio o2 and 3
copies of FGFR2 in 10–39% tumour cells and o10% tumour cells
having X4 copies of FGFR2; disomy (score 1): two copies of
FGFR2 in 90% of tumour cells. Scoring was performed indepen-
dently by two observers at AstraZeneca.
Assessment of FGFR2 amplification heterogeneity. Intratumoral
FGFR2 amplification heterogeneity was assessed in TMA and full
sections from 26 UK cases with FGFR2 amplification, and was
defined as the presence of areas with different FISH scores within
the same tumour in full sections and presence of different FISH
scores in cores from the same tumour in TMA sections. Scoring
was performed independently by two observers.
HER2 FISH. HER2/CEP17 probe (Vysis, 30-161060) was used
according to the manufacturer’s instructions. Fifty tumour nuclei
were scored/case. Tumours with an average HER2 gene copy
number 46 or a HER2/CEP17 ratio X2 were defined as HER2
amplified. Scoring was performed independently by two observers.
Combined FGFR2 and HER2 FISH. To detect FGFR2 and HER2
copy number simultaneously, a four-colour FISH probe was
generated. The above FGFR2/CEP10 probes were combined with a
HER2 probe generated by labelling BAC RP11-94L15 DNA
(Invitrogen) with Spectrum Gold (ENZO, ENZ-42843) and a
CEP17 Spectrum Aqua probe (Vysis, 32-111017) as internal
control using experimental conditions described for FGFR2 FISH.
This analysis was performed only in cases identified as FGFR2 and
HER2 amplified in the TMA. Scoring was performed indepen-
dently by two observers.
Statistical analysis. Data from each cohort were analysed
individually. The following variables were used for statistical
analysis: tumour histology type (Laure´n classification, (Lauren,
1965)) tumour grade of differentiation (WHO classification,
(Hamilton and Aaltonen, 2000)) depth of invasion (pT), lymph
node status (pN), distant metastasis status (pM), resection margin
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status (R) and stage (TNM classification sixth edition) (Sobin and
Wittekind, 2002).
Chi-square tests were used to compare clinicopathological
characteristics between cohorts. For association of FGFR2
amplification with clinicopathological characteristics, logistic
regression models were fitted in both univariate and multivariate
analysis, and P-values were computed by log-likelihood Chi-square
test. In multivariate models, age, gender and factors that showed
significant association in univariate analysis (pN and grade of
differentiation) were included.
For OS, patients were categorised by FGFR2 status into amplified
(FISH score 6) and non-amplified (FISH score 1–5). Data were
analysed using Kaplan–Meier (Kaplan and Meier, 1958) and log-
rank statistics. Univariate and multivariate Cox proportional hazard
models were fitted to evaluate FGFR2 status including variables for
age, gender, grade of differentiation and stage (Sobin and Wittekind,
Table 1. Comparison of the clinicopathological characteristics between UK, Chinese and Korean gastric cancer cohorts
UK cohort (n¼408) Chinese cohort (n¼197) Korean cohort (n¼356)
Characteristic n % n % n %
Age (years)
Median 70 62 59
Range 13–96 18–87 28–82
Gender
Male 255 62.5 133 67.5 247 69.4
Female 153 37.5 64 32.5 109 30.6
Grade of differentiation
G1 45 11.0 3 1.5 20 5.6
G2 103 25.2 40 20.3 173 48.6
G3 250 61.3 133 67.5 161 45.2
G4 1 0.2 21 10.7 2 0.6
Unknown 9 2.2 0 0.0 0 0.0
Laure´n subtype
Intestinal 244 59.8 66 33.5 170 47.8
Diffuse 96 23.5 87 44.2 172 48.3
Mixed 64 15.7 44 22.3 14 3.9
Unknown 4 1.0 0 0.0 0 0.0
Stage
I 115 28.2 15 7.6 121 34.0
II 81 19.9 45 22.8 83 23.3
III 151 37.0 100 50.8 89 25.0
IV 60 14.7 37 18.8 63 17.7
unknown 1 0.2 0 0.0 0 0.0
Depth of invasion (pT)
T1 56 13.7 7 3.6 67 18.8
T2 140 34.3 20 10.2 167 46.9
T3 201 49.3 157 79.7 114 32.0
T4 11 2.7 13 6.6 8 2.2
Lymph node status (pN)
N0 136 33.3 51 25.9 121 34.0
N1 163 40.0 88 44.7 127 35.7
N2 68 16.7 34 17.3 58 16.3
N3 40 9.8 24 12.2 50 14.0
Distant metastasis (pM)
M0 391 95.8 182 92.4 334 93.8
M1 17 4.2 15 7.6 22 6.2
Adjuvant chemotherapy
No 408 100.0 36 18.3 146 41.0
Yes 0 0.0 129 65.5 188 52.8
Unknown 0 0.0 32 16.2 22 6.2
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2002). Statistical tests were two-sided, Po0.05 was considered
significant. Analyses were carried out using R (version 2.10.1).
All studies were performed with the approval of Local Research
Ethics committees and were conducted in accordance with the
Declaration of Helsinki.
RESULTS
Comparison of patient characteristics and clinicopathological
variables between GC cohorts are detailed in Table 1. UK patients
were significantly older at the time of diagnosis compared with
Asian cohorts (UK/Chinese Po0.0001, UK/Korean P¼ 0.0003).
The frequency of intestinal type GC was significantly higher in the
UK cohort compared with Asian cohorts (UK/Chinese Po0.0001,
UK/Korean Po0.0001). The frequency of well, moderately and
poorly differentiated GC was different between all cohorts (UK/
Chinese Po0.0001, UK/Korean Po0.0001, Chinese/Korean
Po0.0001). There was a significant difference in disease stage
distribution between cohorts, with stage III disease more common
in Chinese patients (UK/Chinese Po0.0001, Chinese/Korean
Po0.0001). All UK patients were treated by surgery alone, while
66% of Chinese and 53% of Korean patients received adjuvant
chemotherapy. No patients received neoadjuvant chemotherapy or
radiotherapy.
FGFR2 copy number. Results were obtained from a total of 961
cases (Table 2). FGFR2 amplification frequency was 7.4%, 4.6% and
4.2% in the UK, Chinese and Korean cohorts, respectively, and did
not differ significantly (UK/Chinese P¼ 0.258, UK/Korean
P¼ 0.092, Chinese/Korean P¼ 0.983, UK/Chinese/Korean
P¼ 0.586). FGFR2 polysomy was observed in 35.1%, 44.2% and
21.3% of UK, Chinese and Korean cohorts, respectively, and was
significantly lower in the Korean cohort (UK/Korean Po0.0001,
Korean/Chinese Po0.0001, UK/Chinese/Korean Po0.0001).
Correspondingly, there was a significantly higher frequency of
FGFR2 disomy in the Korean cohort (UK/Korean Po0.0001,
Korean/Chinese Po0.001, UK/Chinese/Korean Po0.001).
Association of FGFR2 copy number with clinicopathological
parameters. The relationship between FGFR2 amplification and
clinicopathological parameters was analogous between the cohorts;
hence, a combined analysis of all three cohorts is presented.
Univariate and multivariate analyses of all 961 patients showed
that FGFR2 amplification was significantly more common in
patients with higher pN category (Po0.0001). For the analysis of
grade of tumour differentiation, the small number of patients with
grade 4 tumours (n¼ 24) were grouped together with grade 3
tumours. Statistical analysis showed that the prevalence of FGFR2
amplification was significantly lower in grade 2 (moderately
differentiated) tumours compared with grade 1 (well differentiated)
or grade 3 and 4 (poorly differentiated/undifferentiated) tumours
(Po0.01). There was no association of FGFR2 amplification with
age, gender, histological subtype (Table 3) or tumour location
(P¼ 0.716, data not shown).
Association of FGFR2 copy number with overall survival. Type
of treatment and other patient characteristics differed significantly
between the three cohorts. Therefore, the relationship between
FGFR2 FISH status and overall survival was analysed separately.
Median OS was significantly shorter in patients with FGFR2
amplified GC compared with patients with FGFR2 non-amplified
GC in UK (Po0.0001) and Korean (P¼ 0.0073) cohorts by
univariate analysis (Table 4). A similar trend was observed for the
Chinese cohort but did not achieve significance (P¼ 0.0646;
Figure 1). Multivariate survival analysis from the Cox proportional
hazard model adjusting for age, gender and grade of tumour
differentiation confirmed FGFR2 amplification status as an
independent prognostic marker in the UK cohort (P ¼ 0.0002;
Table 4).
To assess whether there was an effect of adjuvant chemotherapy
treatment on the prognostic value of FGFR2 amplification, a subset
analysis was performed in patients treated by surgery only vs
patients treated by adjuvant chemotherapy after surgery. Results
from Korean and Chinese cohorts were pooled for this analysis.
FGFR2 amplification was similarly predictive for shorter OS in
patients treated with adjuvant chemotherapy (P¼ 0.002) and the
surgery only group (P¼ 0.03).
UK and Korean patients with FGFR2 polysomy GC (score 4–5)
had a significantly shorter OS when compared with others with
FGFR2 non-amplified disease (score 1–3) in univariate analysis
Table 2. FGFR2 FISH analysis
UK cohort (n¼408) Chinese cohort (n¼197) Korean cohort (n¼356)
FGFR2 FISH score n % n % n %
Disomy 142 34.8 39 19.8 190 53.4
Low trisomy 65 15.9 51 25.9 63 17.7
High trisomy 28 6.9 11 5.6 12 3.4
Low polysomy 87 21.3 51 25.9 66 18.5
High polysomy 56 13.7 36 18.3 10 2.8
Gene amplification 30 7.4 9 4.6 15 4.2
P-valuesa (univariate) P-valuesb (multivariate)
FGFR2 FISH score UK vs Chinese UK vs Korean
Chinese vs
Korean
UK vs Chinese vs
Korean
1–5 vs 6 0.2584 0.0921 0.9827 0.5855
1–3 vs 4–5 0.0664 8.96 10 8 1.90 10 8 3.73 10 9
Abbreviations: FGFR2¼ fibroblast growth factor receptor 2; FISH¼ fluorescent in situ hybridisation.
aP-values contrasted for a given pair of cohorts are computed from w2-test by collapsing score 1–5 subjects in 1–5 vs 6 comparison and score 1–3 and score 4–5 subjects, respectively, in 1–3 vs
4–5 comparison.
bMultivariate P-values are from a log-likelihood ratio test after adjusting for age, gender, stage, grade and Lauren subtype.
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(UK cohort P¼ 0.0427; Korean cohort P¼ 0.0434) that was not
significant in multivariate analysis adjusting for age, gender, grade
of differentiation and stage (Table 4). No relationship was seen in
the Chinese cohort.
FGFR2 amplification heterogeneity. Seven of 29 UK FGFR2
amplified GCs (24.1%) displayed intratumoral heterogeneity
within TMAs. Tissue sections were unavailable for 3/29 GCs.
Analysis of full sections confirmed FGFR2 amplification in 23/26
cases and intratumoral heterogeneity in six cases, which also
showed heterogeneity in the TMA study. Three cases found to be
FGFR2 amplified in the TMA study showed no evidence of FGFR2
amplification in full sections, most likely related to FGFR2
amplification heterogeneity.
FGFR2 and HER2 amplification are predominantly exclusive.
HER2 FISH results were available from 204 and 338 of Chinese and
Korean GCs; amplification was present in 14.7% and 8% of GCs,
respectively. Co-amplification of HER2 and FGFR2 was present in
one Chinese GC but not detected in any GCs from the Korean
cohort. In the UK cohort, the frequency of HER2 and FGFR2
co-amplification was investigated in 26 full sections of GCs found
to be FGFR2 amplified in the TMA study. Two of the 26 UK GC
cases showed FGFR2 and HER2 co-amplification. In order to assess
whether co-amplification was present in the same cell, FGFR2/
HER2 four-colour FISH was performed. High-level amplifications
of HER2 and FGFR2 (FGFR2 average copy number 4100 and
HER2/CEP17 ratio 410) were found in both UK GCs, and HER2
amplification was seen in tumour cells that were FGFR2 non-
amplified and vice versa (Figure 2D). In contrast, HER2 and
FGFR2 amplifications occurred in the same tumour cell in the
single Chinese GC, but amplifications were of low level and only
just satisfied the minimal amplification criteria (FGFR2 average
copy number 5.52 and HER2/CEP17 ratio 2.26) (Supplementary
Figure 1).
Table 3. Comparisons of clinicopathological characteristics by FGFR2 amplification status
FGFR2 non-amplified (FISH 1–5) FGFR2 amplified (FISH 6)
Characteristics n % n % P-value (uni) P-value (multi)a
Age
omedian age 444 95 25 5
Xmedian age 462 94 29 6 0.1873
Gender
Male 602 95 33 5
Female 305 94 21 6 0.7480
Grade
1 64 94 4 6
2 309 98 7 2
3 501 92 43 8
4 24 100 0 0 0.0176 0.0073
Laure´n subtype
Intestinal 459 96 21 4
Diffuse 329 93 26 7
Mixed 115 94 7 6 0.1793 0.2248
Stage
1, 2 442 96 18 4
3, 4 464 93 36 7 0.1021 0.1442
T
1 126 97 4 3
2 306 94 21 6
3 444 94 28 6
4 31 97 1 3 0.5671 0.4805
N
0 304 99 4 1
1 356 94 22 6
2 146 91 14 9
3 100 88 14 12 1.2210 5 o0.0001
M
0 856 94 51 6
1 51 94 3 6 0.4456 0.4281
aP-value is calculated from logistic regression adjusting for age and gender.
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DISCUSSION
FGFR amplification has been reported in various cancers, including
FGFR1 amplification in ERþ breast cancer and squamous cell lung
cancer, and FGFR2 amplification in triple negative breast cancer
and GCs (Andre et al, 2009; Turner et al, 2010a, b; Weiss et al,
2010; Deng et al, 2012; Dulak et al, 2012; Jung et al, 2012;
Matsumoto et al, 2012; Nadauld et al, 2012). Hence, there is
significant interest in FGFR2 as a therapeutic target for FGFR2-
amplified GCs, and clinical trials of FGFR inhibitors are ongoing.
There is variability in the reported incidence of FGFR2
overexpression in GC; FGFR2 protein overexpression was reported
to be 30%–40% by immunohistochemistry, (Hattori et al, 1996)
while the incidence of FGFR2 amplification varies from 3 to 10%
(Mor et al, 1993; Hara et al, 1998; Deng et al, 2012; Dulak et al,
2012; Jung et al, 2012; Matsumoto et al, 2012). Gene copy-number
evaluation in solid tumour cells by FISH is widely accepted as a
‘gold-standard approach’ for clinical application, and the current
study is the largest to date assessing FGFR2 amplification by FISH
in patients with resectable GC from three different countries,
Korea, China and UK. The prevalence of FGFR2 amplification was
investigated in a total of 961 GCs and was 7.4%, 4.6% and 4.2% in
UK, Chinese and Korean GCs, respectively, with no significant
difference of incidence between cohorts. Our results are similar to
those reported previously for Korean (Jung et al, 2012) and
Japanese cohorts (Matsumoto et al, 2012). In addition to FGFR2
amplification, we found a significant incidence of FGFR2 polysomy
in GC, which was significantly higher in UK (35.1%) and Chinese
(44.2%) GC cohorts than in the Korean cohort (21.3%). Further
work is required to demonstrate whether FGFR2 polysomy is
related to tumour growth, survival and sensitivity to therapeutic
intervention.
The observation that FGFR2 amplification was significantly
associated with lymph node disease suggests that this molecular
aberration may contribute to the development of metastasis. An
association between FGFR2 amplification and lymphatic invasion
was recently reported (Jung et al, 2012).
It has been reported that FGFR2 amplification is more
frequently found in diffuse type GC compared with intestinal type
GC (Nakatani et al, 1990). In contrast, our study did not find an
association of FGFR2 amplification with histological subtype
according to the Laure´n classification, which is in agreement with
findings recently reported for another Korean GC cohort (Jung
et al, 2012). This contrasts with HER2 gene amplification, which is
associated with the intestinal subtype of gastric cancer (Bang,
2012).
The current study suggests that FGFR2 amplification is a
molecular factor related to poor prognosis in patients with
resectable GC, irrespective of ethnic origin and irrespective of
the underlying significant differences in clinicopathological para-
meters, survival and treatment between cohorts from Asia and the
United Kingdom. The potential usefulness of FGFR2 amplification
as a predictive factor for response to FGFR2 targeting therapies
remains to be evaluated in patients with GC.
Amplification of HER2 has been identified in 6–35% of patients
with GC (Bang, 2012); however, the majority of recent studies have
reported incidences of 6–13% (Okines et al, 2012; Terashima et al,
2012; Narita et al, 2013; Warneke et al, 2013; Aizawa et al, 2014).
HER2 amplification has led to the successful development and
approval of trastuzumab in patients with GC (Bang et al, 2010).
In the present study, we assessed the overlap between FGFR2 and
HER2 amplification. Only 3/50 FGFR2-amplified samples (3/961 of
total population samples) were also HER2 amplified, confirming
that HER2 and FGFR2 amplifications are usually mutually
exclusive (Deng et al, 2012). Interestingly, low-level HER2 and
FGFR2 amplifications were detected in the same tumour cells inT
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one Chinese GC, whereas in two UK GCs tumour cells with high-
level HER2 amplification were located in a different area to tumour
cells with high-level FGFR2 amplification. The findings in these
latter two GCs suggest that FGFR2- and HER2- amplified tumour
cells may have developed from different tumour cell clones with
differing genetic characteristics. In these patients, combined FGFR2
and HER2 inhibitor therapies might be required for durable and
potent antitumour responses.
We found evidence for intratumoral heterogeneity of FGFR2
amplification in about 25% of GCs, indicating that there is a
potential for missing areas of amplification especially when
analysis is performed on small biopsies, rather than sections from
resection specimens. Similar intratumoral heterogeneity has been
reported for HER2 amplification in GC, leading to a recommenda-
tion that multiple biopsies should be assessed to determine HER2
status of a tumour.
In conclusion, this is the largest study of FGFR2 FISH in GC and
the first study to compare the incidence of FGFR2 amplification in
UK and Asian cohorts, demonstrating a similar incidence across
cohorts. Furthermore, our data show that FGFR2 amplification is
associated with lymph node metastasis and related to poor OS.
Overall, this study suggests that FGFR2 may represent an attractive
therapeutic target in a subgroup of GCs, irrespective of ethnicity,
and FISH methodology could be used for patient selection.
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Figure 1. Kaplan–Meier OS analysis using FGFR2 FISH score in three separate patient cohorts. Median OS and 95% CI for pairwise comparisons
are provided.
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Figure 2. Dual-colour FISH shows FGFR2 copy-number normal (A), copy-number increase (B) and amplification (C). Red and green signals
highlight FGFR2 gene and centromere 10 probes, respectively. Four-colour FISH reveals distinct tumour regions with either FGFR2 or HER2
amplification (D). Gold and aqua probes highlight HER2 and centromere 17.
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